This session includes a clinically focused debate on the evolving role of interventional strategies — including catheter-directed thrombolysis and surgical embolectomy — versus optimized medical therapy in the management of VTE. The session critically evaluates current evidence, patient selection criteria, risk-benefit considerations, and the growing armamentarium of endovascular options for pulmonary embolism and DVT.

Approach to Provoked vs. Unprovoked Venous Thromboembolism

This session will cover a critical and balanced appraisal of the major anticoagulant classes: DOACs, LMWH, and Vitamin K antagonists ; contextualizing their roles across VTE indications. The session focuses on practical prescribing considerations, patient-specific factors influencing drug choice, monitoring requirements, reversal strategies, and aligning therapy with guidelines and real-world clinical constraints.

Putting DOACs, LMWH, oral anticoagulants in the right perspective

Day 2 of the Review of Current Practices (RCP) on venous thromboembolism (VTE) builds on foundational concepts with a sharper focus on high-risk scenarios and evolving treatment paradigms. Chaired by Lt Gen (Dr.) Velu Nair (Retd.), the day features 4 expert-led sessions designed to refine clinical decision-making.

The evening begins with a recap of key Day 1 insights, followed by a keynote by Dr. Velu Nair on cancer-associated thrombosis, addressing treatment complexities in high-risk patients. Then presents emerging evidence in anticoagulation, with insights from the COBRRA trial and its clinical implications.

Subsequent sessions include rationalizing the use of DOACs, LMWH, and oral anticoagulants, and a discussion on selecting between interventional and medical management strategies in VTE.

The program concludes with closing remarks and key takeaways, reinforcing practical application. As with Day 1, the format remains highly interactive with live polls, audience engagement, and knowledge assessments, ensuring meaningful learning outcomes for participants.

RCP VTE 2026 - Day 2

An interactive panel discussion on personalizing VTE management in challenging patient populations. Led by Dr. Velu Nair, the session tackles clinical grey zones, including obesity, active bleeding risk, stroke prevention in atrial fibrillation (SPAF), renal failure, and VTE in young adults, providing nuanced, individualized approaches grounded in current evidence and real-world practice.

From Guidelines to Ground Reality: Personalizing VTE Management in the Grey Zone Population

The Review of Current Practices (RCP) on venous thromboembolism (VTE) kicks off with a focused and clinically rich Day 1, chaired by Lt Gen (Dr.) Velu Nair (Retd.). Designed for busy clinicians, the evening features 3 expert-led sessions that lay the foundation for evidence-based VTE management.

The agenda begins with an overview of contemporary approaches, followed by a discussion of thromboprophylaxis and risk stratification, emphasizing translation of evidence into real-world clinical decision-making. This is complemented by a session on catheter-related thrombosis, bringing in interventional and surgical perspectives.

The day culminates in an in-depth panel discussion, focusing on personalizing VTE management in complex “grey zone” populations, including obesity, bleeding risk, renal dysfunction, and young adults.

With interactive elements such as live polls, audience Q&A, and case-based insights, Day 1 sets the stage for a practical, nuanced understanding of VTE management. Participants will also engage through pre–post assessments, with certificates awarded upon completion.

RCP VTE 2026 - Day 1

Antiphospholipid Antibody (APLA) Syndrome presents diagnostic challenges and requires nuanced long-term management to prevent recurrent thrombosis. Chaired by Dr Tulika Seth, with panelists Dr Ranjan Gupta and Dr Abhay Bhave, this session will cover updated diagnostic criteria, clinical scenarios, and therapeutic strategies for this complex autoimmune-mediated prothrombotic disorder.

Navigating APLA Syndrome: From Diagnosis to Thrombosis Management

Review in Current Practice in Venous Thromboembolism is a two-day live virtual conference dedicated to advancing the understanding and management of VTE. Join leading experts as they explore emerging science, evolving risk stratification tools, and modern therapeutic strategies across diverse patient populations. This focused update on thrombosis care offers clinicians practical, evidence-based insights to improve outcomes across inpatient, outpatient, and high-risk settings.
Key Topics
Innovations in VTE: Advances in diagnostics, risk prediction, and the future of thrombosis care
Inpatient to Post-Discharge: Continuum of VTE prevention in hospitalized medical patients
Risk Stratification 2.0: Newer techniques using biomarkers & imaging advancements
Specialised care: including VTE management in women and the elderly
Procedural Interventions in DVT: What every physician should know about IVC filters and venous stents
Cancer-Associated Thrombosis: Personalized anticoagulation and new therapy frontiers
Managing APLA Syndrome: From diagnosis to long-term thrombosis prevention
This comprehensive review will help refine your clinical decision-making in VTE care. Stay updated, stay prepared-Register now to secure your spot.

RCP VTE Day 2

Special populations often face unique VTE risks that demand tailored management strategies. Chaired by Dr Tulika Seth, with panelist Dr Raghuram Sekhar, this session will examine gender- and age-specific considerations, hormonal influences, and postpartum physiology to refine patient-centered thrombosis care.

VTE management in special populations - Women, elderly and postpartum - non lactating women.

Many patients face a high risk of VTE both during hospitalization and in the vulnerable post-discharge phase. Chaired by Dr Vivekanand with keynote by Dr Kumud Rai, this session will explore evidence-based inpatient protocols, transitional care strategies, and best practices to ensure continuous protection against VTE-related complications.

Continuum of VTE Care: Inpatient strategies for medical patients and Post-Discharge protection

Despite significant progress in thrombosis research, venous thromboembolism (VTE) remains a leading cause of preventable hospital deaths. This session, chaired by Dr Tulika Seth with keynote by Dr Alexander Cohen, will set the stage for the conference—highlighting recent breakthroughs, ongoing challenges, and the evolving landscape of VTE prevention and treatment.

Inaugural Session: Advances in VTE: Innovations, Challenges, and the Future of Thrombosis Care

RCP VTE Day 1

Dr. Tulika Seth presents an in-depth session, summarizing the key insights from RCP - VTE. Join us for this essential discussion where you'll get a comprehensive overview of the latest advancements, strategies, and research findings shared at the conference. Don't miss this chance to consolidate your knowledge and stay updated in the field of VTE.

RCP - Venous Thromboembolism

Participate in an insightful live session with Dr. Abhay Bhave and Dr. Tulika Seth on optimizing anticoagulant therapy. This session will compare the safety and efficacy of traditional anticoagulants (warfarin, heparin) with newer oral options (NOACs). We will review current guidelines from ACCP, ESC, ASH, NCCN, and NICE, and discuss recommendations for anticoagulant use in diverse patient groups, including those undergoing total hip or knee replacement for primary prophylaxis. Explore the impact of guideline-directed therapy on patient outcomes and clinical practice and evaluate how standardized protocols can enhance treatment consistency. Don’t miss this opportunity to refine your approach to anticoagulant management.

Current Practices in the Prophylaxis of VTE

Be a part of an essential live session with Dr. Tulika Seth and Dr. Abhay Bhave on VTE risk assessment and management. This session will cover the Caprini Risk Assessment Model’s key components and clinical applications, along with the Wells Score for Deep Vein Thrombosis (DVT) and the revised Geneva Score for Pulmonary Embolism (PE), including their uses and limitations. We’ll explore the PESI (Pulmonary Embolism Severity Index) for assessing PE severity, the Hestia Criteria for evaluating hospitalization needs in PE patients, and how to tailor risk assessment models for special populations such as the elderly, obese individuals, CKD or cancer patients, pregnant/post-partum women, and pediatric patients. Enhance your risk assessment skills.

Diagnosis and Risk Assessment in VTE

Join leading experts Dr. Alexander Cohen, Lt Gen (Dr) Velu Nair, Dr. Tulika Seth, and Dr. Abhay Bhave for a series of live sessions on Venous Thromboembolism (VTE). These sessions will delve into the incidence, prevalence, and risk factors of VTE, with a focus on diagnostic challenges and the impact on special populations. Explore the pathophysiology of VTE, compare traditional and modern anticoagulant therapies, and refine your risk assessment skills using key models like the Caprini, Wells, and Geneva Scores. Enhance your understanding and management of VTE to improve patient outcomes in clinical practice.

Professor of Haematology, AIIMS, New Delhi

Haemophilia care is evolving rapidly, with the focus extending beyond simply preventing and treating bleeding episodes to improving long-term outcomes and quality of life. This masterclass will take clinicians through the complete care pathway from recognising clinical clues and identifying patients who may have haemophilia to diagnosis, referral, treatment, monitoring and long-term management. It will explore the evolving treatment landscape, including the role and challenges of factor replacement therapy and the emergence of non-factor therapies. The session will also take a deeper look at non-factor prophylaxis in Haemophilia A and B without inhibitors, bringing together clinical evidence and real-world experience on bleed control and quality-of-life outcomes.

Haemophilia Masterclass 2026

Rather than focusing only on haemophilia treatment, the session takes you from the first clinical suspicion through diagnosis, referral and long-term care, helping physicians recognise patients earlier and navigate the care pathway more effectively.
Why attend?
- Learn to spot the early clinical clues that may indicate haemophilia, even when bleeding history is not obvious.
- Understand when to suspect haemophilia and initiate the diagnostic work-up.
- Gain clarity on the diagnosis-to-HTC referral pathway and appropriate next steps.
- Understand key considerations in treatment, monitoring and long-term management.
- Take away a more structured approach to recognising and managing patients with suspected bleeding disorders in routine practice.

Beyond the Bruise: Early Identification of Bleeding Disorders

This session takes a broader view of treatment success, exploring how newer non-factor approaches are changing haemophilia care and addressing outcomes beyond bleed control, including quality of life.

Why attend?
This session will help doctors understand the evolving approach to haemophilia treatment, beginning with the role of factor replacement and the practical challenges that can affect treatment outcomes, including inhibitor development, venous access, adherence and breakthrough bleeds. Attendees will also gain an understanding of non-factor therapies and their potential role in addressing some of these challenges while improving patient outcomes.

Evolving Treatment Landscape

The session moves from evidence to experience, bringing together clinical evidence and real-world data to provide a practical perspective on the effectiveness of non-factor prophylaxis and its potential to improve outcomes beyond simply preventing bleeds.

Why attend?
This session will help doctors build a deeper understanding of non-factor prophylaxis in haemophilia A and B without inhibitors, with a focus on its impact on bleed control and quality of life. Attendees will explore the evidence supporting these approaches and gain insights into how clinical outcomes translate into real-world patient care.

Dr. Tulika Seth

20

7k

321.3k

4.8

Upcoming Sessions

Sessions Taken

293

4.9

387

4.7

533

4.8

357

4.8

531

4.7

1.1k

4.7

844

4.8

915

4.7

1.1k

4.7

1.1k

4.7

1k

4.7

2.2k

0

2.2k

0

2.2k

0

2.2k

4.8